United States: Bristol-Myers Squibb And AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation - Goodwin Procter LLP

United States: Bristol-Myers Squibb And AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation - Goodwin Procter LLP

Mondaq

Published

We previously reported on Bristol-Myers Squibb's ("BMS") complaint alleging AstraZeneca's PD-L1 antibody product, IMFINZI (durvalumab), infringed U.S. Patent No. 9,402,899

Full Article